FDA Advisory Committee Recommends Six of Seven Peptides for the 503A Compounding List: What It Means for Your Business

From the Magazine
This story appears in the September–October 2026 issue of Dispense Times.

By Guilherme Ferrari Faviero, Esq., MS, MPH; Jesse C. Dresser, Esq.; and Edgar J. Asebey, Esq., Frier Levitt

Introduction

On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (“PCAC”) convened for what many in the industry have described as the most consequential regulatory event for the peptide space in years. Over the course of two days, the reconstituted PCAC considered whether seven unapproved peptide bulk drug substances should be added to the list of substances eligible for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act (“FD&C Act”), the so-called “503A Bulks List.”

The meeting unfolded against a charged political backdrop.

U.S. Health and Human Services (“HHS”) Secretary Robert F. Kennedy Jr. has been publicly vocal about his desire to expand patient access to peptides, characterizing existing restrictions as having created a “very dangerous” black market. At the same time, the FDA’s own scientific reviewers had recommended against the inclusion of all seven peptides, citing insufficient clinical data, inadequate chemical characterization, and unresolved safety concerns.

Secretary Kennedy’s Role in the Review Process

Secretary Kennedy’s public advocacy has shaped this process in concrete ways. In February 2026, he moved roughly fourteen of nineteen Category 2 peptides back to Category 1, and in April 2026, he directed that the seven peptides at issue be removed from Category 2 and re-evaluated by “independent experts.” The reconstituted PCAC that conducted the July review included eight new members appointed that June, several with disclosed financial ties to peptide-related medical practices. This does not mean the committee’s conclusions were predetermined, but any final rule adopting the PCAC’s recommendations should anticipate scrutiny over the committee’s composition and Secretary Kennedy’s role in framing the review, which could become a feature of any Administrative Procedure Act challenge.

In a series of closely divided votes, the PCAC ultimately recommended that six of the seven peptides under review be added to the 503A Bulks List. Only emideltide (also known as delta sleep-inducing peptide, or “DSIP”) received a majority of “no” votes. This article provides a detailed summary of the committee’s findings, analyzes the legal and regulatory implications for key stakeholders across the peptide industry, and identifies the critical open questions that industry participants should be monitoring in the weeks and months ahead.

Regulatory Background: The 503A Bulks List and the PCAC Process

Section 503A of the FD&C Act sets forth the conditions under which compounded drug products prepared by licensed pharmacists or physicians may be exempt from certain statutory requirements, including the FDA new drug approval process, current good manufacturing practice (“cGMP”) requirements, and certain labeling requirements. A threshold condition for this exemption is that the compounder must use bulk drug substances that either (1) comply with applicable USP or NF monographs, (2) are components of FDA-approved drugs, or (3) appear on the 503A Bulks List.

None of the seven peptides reviewed by the PCAC meet the first two conditions. None has a USP or NF monograph, and none is a component of any FDA-approved drug product. Accordingly, the only lawful pathway for 503A compounding of these peptides is their inclusion on the 503A Bulks List, which the FDA populates through notice-and-comment rulemaking after considering the following four evaluation criteria, published in the Federal Register on February 19, 2019 (84 FR 4696):

• The physical and chemical characterization of the substance;
• Any safety issues raised by the use of the substance in compounded drug products;
• The available evidence of the effectiveness or lack of effectiveness of a drug product compounded with the substance, if any such evidence exists; and
• Historical use of the substance in compounded drug products, including information about the medical condition(s) the substance has been used to treat and any references in peer-reviewed medical literature.

In applying these criteria, the FDA employs a “balancing test,” weighing each factor in the context of the others on a substance-by-substance basis. The PCAC’s role is to provide independent expert advice and nonbinding recommendations to the agency regarding these substances; the ultimate decision to add or decline to add a substance to the 503A Bulks List rests with the FDA.

Notably, the original nominations for all seven peptides were withdrawn by their respective nominators, LDT Health Solutions, Inc. (on behalf of the International Peptide Society) and Wells Pharmacy Network.

The FDA nonetheless elected to proceed with the evaluations at its own discretion, a procedural decision that underscores the agency’s recognition of the significance of these substances to public health and industry alike.

FDA Staff’s Scientific Basis for Recommending Against All Seven Peptides

Before the PCAC voted, the FDA’s career scientific reviewers applied the four-factor balancing test to each peptide and reached a uniform recommendation against inclusion, based on three recurring reasons. First, there were characterization gaps: most peptides lack USAN, INN, or IUPAC names and a USP or NF monograph, and several nominations did not specify whether the free base or acetate salt form was under review. Second, there were thin or absent human clinical data. The FDA found none at all for KPV and MOTS-c, and only a decades-old, unpublished abstract for BPC-157 using an oral rather than injectable route. Third, there were unresolved safety signals, including BPC-157’s theoretical tumor-growth risk from its angiogenic mechanism and uncharacterized immunogenicity across the class. The FDA acknowledged the peptides’ popularity but concluded that the statutory factors did not support inclusion for any of the seven.

The PCAC’s Recommendations: A Substance-by-Substance Summary

Across all fourteen individual votes—covering both the free base and acetate salt forms of each of the seven peptides—the PCAC recommended inclusion on the 503A Bulks List for six substances. The votes were closely divided throughout, with the committee diverging from the FDA’s scientific staff recommendations against inclusion. The table below summarizes the outcomes:

Day One: July 23, 2026

BPC-157 (Body Protection Compound-157), one of the most widely recognized peptides in the wellness and clinical compounding space, was evaluated for its proposed use in treating ulcerative colitis. BPC-157 has generated significant interest in clinical practice due to nonclinical studies suggesting gastrointestinal protective properties, wound healing potential, and anti-inflammatory effects. While FDA reviewers noted gaps in chemical characterization data and limited human clinical trials, the PCAC weighed these considerations against the substance’s substantial body of nonclinical research, its documented history of use in compounding practice, and strong demand from patients and providers. The committee voted in favor of inclusion.

KPV, a tripeptide with documented anti-inflammatory properties, was reviewed for wound healing and inflammatory conditions. Although the FDA characterized KPV as not yet fully characterized under its evaluation criteria, the committee recognized the substance’s therapeutic potential and the clinical interest supporting its use. The PCAC voted to recommend its inclusion on the 503A Bulks List.

TB-500, a synthetic peptide fragment of thymosin beta-4 with reported wound healing and tissue repair properties, was evaluated for subcutaneous and intramuscular administration. FDA staff noted the limited scope of existing clinical data, but the committee weighed this against the peptide’s established use in compounding practice and the growing body of nonclinical evidence supporting its therapeutic applications. The PCAC voted in favor of inclusion.

MOTS-c, a mitochondrial-derived peptide that has attracted attention for its potential metabolic benefits, was reviewed for metabolic conditions. While the FDA applied the same evaluation framework and identified similar characterization gaps, the committee determined that the available evidence and clinical demand supported inclusion. The PCAC voted to recommend its addition to the list.

Day Two: July 24, 2026

Emideltide (DSIP) was the sole peptide for which the PCAC sided with the FDA’s recommendation against inclusion. Evaluated for proposed uses including opioid withdrawal, chronic insomnia, and narcolepsy, the committee found the current data insufficient to support inclusion at this time. The vote was close at 7–6, with one abstention, for both the free base and acetate forms. PCAC member Bobby Harshbarger, PharmD, notably emphasized the distinction between the 503A compounding standard and the investigational new drug standard, stating: “This vote doesn’t approve a drug or indication. It permits patient-specific compounding under a valid prescription.”

Epitalon, a tetrapeptide studied for its effects on melatonin regulation, was proposed for the treatment of insomnia. FDA reviewers raised theoretical concerns about immunogenicity, and the committee carefully considered these concerns alongside the substance’s profile and clinical interest. Ultimately, the PCAC voted 7–5, with one abstention, to recommend inclusion, reflecting the committee’s judgment that the balance of factors favored making epitalon available for compounding.

Semax, a heptapeptide analogue of ACTH with documented neuroprotective properties, was evaluated for cerebral ischemia, migraine, and trigeminal neuralgia. Notably, semax has been approved and widely used in Russia for neurological indications, providing a broader context of international clinical experience. The committee voted 8–5, with one abstention, to recommend inclusion, the widest favorable margin of any Day Two peptide.

Throughout the meeting, the PCAC engaged in vigorous debate, weighing FDA staff’s characterization and data concerns against the practical realities of patient access, the growing body of nonclinical and anecdotal evidence, and concerns about moving consumers away from unregulated sources.

PCAC member Dr. Asare Christian of Aether Medicine captured the prevailing sentiment among those who voted in favor, noting: “I think it’s about patient access. As a physician, I’m always quantifying risk … Even when I give somebody gabapentinoids, which are actually FDA approved, there’s all this risk that I have to manage.” The National Association of Boards of Pharmacy (“NABP”) liaison abstained from all three Day Two votes and urged the FDA “to use the time before any final rule to build an infrastructure or framework with NABP and the state boards of pharmacy … such as adverse event reporting.”

Legal and Regulatory Implications

1. Nothing Has Legally Changed Yet

The PCAC’s recommendations are advisory only and do not carry the force of law. As of this writing, these peptides still cannot be lawfully compounded under Section 503A, and the FDA retains full enforcement authority against pharmacies that compound and sell them. As Matthew Lash, acting director of FDA’s Office of Compounding Quality and Compliance, noted during the meeting, the agency’s formal decision-making process will incorporate the full record, including docket comments that were submitted close to the deadline and not reflected in the briefing packages.

For the PCAC’s recommendations to have legal effect, the FDA must undertake formal notice-and-comment rulemaking to add the peptides to the 503A Bulks List.

2. FDA’s Enforcement Posture Remains a Key Variable

While the formal rulemaking process could take months or longer, a critical near-term question is whether and how the FDA will exercise its enforcement discretion during the interim period. The agency could, for example, adopt a Category 1 classification under its existing enforcement discretion policies, effectively deprioritizing enforcement against compounders who use these substances. There is, however, a wrinkle.

The FDA’s interim policy for substances nominated to the 503A Bulks List extends enforcement discretion only to substances appearing in Category 1 on the agency’s website, and the January 2025 revision to that guidance provides that substances nominated on or after January 7, 2025, will not be categorized at all and therefore fall outside the interim policy. Because the nominations for the peptides at issue were withdrawn, none currently appear in any category, and a new nomination would fall on the wrong side of the January 2025 cutoff.

A shift in enforcement posture is therefore possible but would require an affirmative step beyond the existing framework, such as a revision to the interim policy guidance or a standalone statement of enforcement discretion issued outside the category structure. The current interim policy contains certain conditions, including that all manufacturers in the supply chain be registered under Section 510 and that the substance be accompanied by a valid certificate of analysis. Industry participants should monitor FDA guidance documents, Federal Register notices, updates to the agency’s category lists, and public statements from HHS and FDA leadership for indications of a change.

3. Prescribers Should Exercise Restraint

Physicians and other prescribers who utilize peptide therapies should understand that a favorable PCAC recommendation does not equate to a finding of safety or efficacy.

While licensed healthcare practitioners are generally permitted to prescribe FDA-approved drugs for off-label uses, federal law explicitly provides that the FDCA does not interfere with a practitioner’s authority to prescribe legally marketed drugs for conditions not included in FDA-approved labeling, provided there is a legitimate practitioner-patient relationship. This protection does not extend to drugs that have never been approved by the FDA for any use.

When a licensed practitioner prescribes a drug that is not FDA-approved, the legal risks depend on the specific circumstances surrounding the prescription. In the context of prescribing unapproved drugs, courts have found that such actions may constitute the introduction of misbranded drugs into interstate commerce. Additionally, prescribers bear independent professional obligations under state medical practice acts and standards of care.

4. Marketing and Advertising Constraints Are Real

If the FDA ultimately adds these peptides to the 503A Bulks List, businesses across the peptide ecosystem—including compounding pharmacies, telehealth platforms, medical spas, wellness clinics, and direct-to-consumer sellers—should exercise extraordinary care in their marketing and promotional activities. Federal and state advertising and consumer protection laws generally require “competent and reliable scientific evidence” to substantiate health-related claims.

5. The RUO Peptide Market Will Likely Persist, At Least for Now

For most patients and consumers currently using these peptides, a practical source is not a compounding pharmacy but the “research use only” (RUO) marketplace: vials sold online and through wellness clinics labeled “not for human consumption” and typically sourced from overseas, increasingly from Chinese manufacturers. RUO products carry no FDA oversight, sterility guarantees, or pharmacovigilance infrastructure. Whether Bulks List inclusion meaningfully shrinks this market is doubtful in the near term: rulemaking will likely take twelve to twenty-four months, resulting compounding will track only the narrow indications PCAC reviewed (for example, BPC-157 for ulcerative colitis), compounded products will likely cost more than RUO vials, and the five peptides still awaiting review in February 2027 will remain RUO-only in the meantime. The RUO sector should therefore be expected to persist as the dominant access point for these substances for some time, even after a favorable final rule.

That persistence does not mean the RUO channel is unsupervised. Federal enforcement against it has intensified sharply. Since September 2025, the FDA has issued more than fifty Warning Letters to research-peptide vendors, including a cluster of seven letters on April 7, 2026, against sellers marketing peptides and GLP-1 analogues as “research use only” while their own product pages described appetite suppression, weight loss, or glucose regulation. The FDA has taken the position that such disclaimers do not defeat evidence of intended human use.

That action followed a November 2025 sweep of seventeen Warning Letters against online sellers, and a March 2026 wave of roughly thirty letters targeting telehealth platforms and compounding pharmacies over GLP-1 marketing claims, and peptide- and GLP-1-related Warning Letters have roughly tripled since 2024. At least nine RUO vendors have closed since mid-2025 under this pressure, compounded by customs seizures and payment-processor restrictions.

State boards of pharmacy are moving in parallel, and Ohio’s board, for example, fined a Columbus-area pharmacy $15,000 in January 2026 for compounding bulk semaglutide without patient-specific prescriptions and separately disciplined a Cleveland pharmacy for sourcing peptides from unregistered overseas suppliers.

The FTC has likewise become active in this space. Businesses should expect this enforcement triad of FDA, FTC, and state pharmacy boards to keep tightening around unregulated peptide sales regardless of what FDA ultimately decides on the Bulks List.

Most recently, Eli Lilly, the maker of Mounjaro and Zepbound, filed six federal lawsuits against businesses it alleges are illegally selling products purporting to contain retatrutide, its investigational triple-agonist obesity drug, before FDA approval. The defendants include four RUO peptide sellers, a compounding pharmacy, and a med spa. With the exception of the lawsuit against the med spa, which is premised on federal false advertising claims under the Lanham Act, Eli Lilly is proceeding primarily under state consumer protection and unfair competition statutes rather than federal claims. These recent lawsuits are notable for being, to our knowledge, the first time a branded drug maker has taken the RUO peptide sellers to court.

Conclusion: Preparing for a Shifting Regulatory Landscape

The July 2026 PCAC meeting marks a significant event for the peptide industry, but it is the beginning of a process, not its conclusion. The committee’s favorable recommendations for six of the seven reviewed peptides could reshape the regulatory environment for compounding pharmacies, providers, and businesses across the peptide ecosystem.

Underlying all of this is the RUO market that the PCAC process is ultimately trying to address. The FDA, the FTC, and state pharmacy boards are simultaneously tightening enforcement against RUO peptide sales even as the FDA considers whether to legalize compounding of six of these substances, and a favorable final rule is best understood as an attempt to give patients and providers a regulated, prescription-based alternative to that gray market, not a guarantee that the RUO channel will disappear or that enforcement pressure on it will ease.

However, the path from advisory committee recommendation to binding regulatory change is neither automatic nor predictable. Businesses should resist the urge to treat the PCAC vote as a green light and should instead use this period to conduct thorough compliance assessments, evaluate their exposure across both federal and state regulatory frameworks, and develop contingency plans for multiple potential outcomes.

About the Authors

Guilherme Ferrari Faviero, Esq., MS, MPH, is a senior associate in Frier Levitt’s Life Science Group. His practice focuses on FDA regulatory law and compliance, as well as transactional work in the food and drug, biotechnology, cannabis, hemp, and psychedelics sectors. A scientifically trained attorney with graduate degrees in biomedical sciences and public health, he offers a unique perspective to clients in highly regulated industries.

Jesse C. Dresser, Esq., is a partner at Frier Levitt. He counsels pharmacies, pharmacy owners, healthcare providers, and other healthcare businesses on pharmacy law, regulatory compliance, reimbursement, licensing, and government investigations. He regularly advises clients on legal and regulatory developments affecting the compounding industry.

Edgar J. Asebey, Esq., is a partner at Frier Levitt. He advises FDA-regulated companies on complex regulatory, compliance, and enforcement matters involving pharmaceuticals, biologics, medical devices, dietary supplements, and other FDA-regulated products. His scientific background and extensive FDA regulatory experience provide clients with practical guidance on navigating evolving agency policies and enforcement priorities.